Curasight

Curasight A/S reports positive preclinical results with uTREAT® in aggressive brain cancer (glioblastoma)

by

Preclinical studies show uTREAT® efffective in treating aggressive brain cancer Data supports strategy to move uTREAT® into clinical development for evaluation in patients with aggressive brain cancer COPENHAGEN, Denmark, June 7, 2023 /PRNewswire/ — Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) is pleased to announce preclinical data demonstrating the effectiveness of uTREAT® in … Read more

Curasight A/S reports positive preclinical results with uTREAT® in aggressive brain cancer (glioblastoma)

by

Preclinical studies show uTREAT® efffective in treating aggressive brain cancer Data supports strategy to move uTREAT® into clinical development for evaluation in patients with aggressive brain cancer COPENHAGEN, Denmark, June 7, 2023 /PRNewswire/ — Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) is pleased to announce preclinical data demonstrating the effectiveness of uTREAT® in … Read more

Curasight: Interim report Q1 2023

by

COPENHAGEN, Denmark, May 25, 2023 /PRNewswire/ — Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report Q1 2023. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report. Curasight’s CEO Ulrich Krasilnikoff comments: “During the first quarter … Read more